Roivant's brepocitinib achieves clear or almost clear skin in 69% of cutaneous sarcoidosis patients in phase 2 trial
ROIV•Roivant said Phase 2 results for brepocitinib showed improved skin disease activity versus placebo in cutaneous sarcoidosis, with 69% of patients achieving clear or almost clear skin. Patients reported better skin-related quality of life; treatment was well tolerated over 16 weeks, with no serious adverse events.
1. Phase 2 results
Priovant announced publication of Phase 2 brepocitinib results in JAMA Dermatology, showing improved skin disease activity versus placebo in cutaneous sarcoidosis. Sixty-nine percent of patients achieved clear or almost clear skin.
2. Next steps
Patients also reported better skin-related quality of life. Treatment was well tolerated over 16 weeks, with no serious adverse events. The findings support the ongoing Phase 3 BEACON+ trial, with topline data expected in 2028; results will be presented at ACR Convergence 2026.
